Ketamine for Chronic Fatigue Syndrome (CFS/ME)

Ketamine for chronic fatigue syndrome is not an FDA-approved or clinically established treatment. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), also called chronic fatigue syndrome, is a complex illness with no approved pharmacological treatment at all, which is why patients and clinicians have looked at drugs like ketamine that act on biological pathways thought to be involved in the disease. The interest is based on mechanistic overlap and case reports rather than completed clinical trials in ME/CFS patients. This article explains why ketamine is being studied for ME/CFS, what the current evidence actually shows, and what patients should understand about the risks before considering it off-label.

ME/CFS is marked by profound fatigue that does not improve with rest, worsens after physical or cognitive exertion, a pattern called post-exertional malaise (PEM), and comes with neurological, immunological, and autonomic symptoms. According to a 2015 report from the National Academies of Medicine, then known as the Institute of Medicine, ME/CFS affects an estimated 1 to 2.5 million Americans and occurs more often in women than men.

No FDA-approved pharmacological treatment exists for ME/CFS. According to the Centers for Disease Control and Prevention, management currently focuses on treating individual symptoms, since no drug is approved to treat the underlying illness. That treatment gap has driven interest in novel options, including ketamine, a dissociative anesthetic whose known mechanisms of action overlap with several features researchers have observed in ME/CFS patients.

Neuroinflammation. Imaging studies have found widespread activation of microglia, the immune cells of the brain, in ME/CFS patients, particularly in regions involved in cognitive processing, pain, and autonomic regulation. Elevated pro-inflammatory cytokines, including interleukin-6 and tumor necrosis factor-alpha, have also been reported in blood and cerebrospinal fluid. Ketamine has documented anti-inflammatory properties, including suppression of pro-inflammatory cytokine production, which is why researchers have proposed it as a way to address the neuroinflammation linked to brain fog, pain, and fatigue in ME/CFS. Our detailed look at ketamine and neuroinflammation covers this mechanism in more depth.

NMDA receptor dysregulation. The N-methyl-D-aspartate (NMDA) receptor, ketamine's primary pharmacological target, may be dysregulated in ME/CFS. Some researchers have proposed that excess glutamate signaling contributes to neuronal dysfunction in the condition, and elevated glutamate levels have been found in certain brain regions of ME/CFS patients using magnetic resonance spectroscopy. By blocking NMDA receptors, ketamine could theoretically reduce this excitotoxic signaling, a mechanism explained further in our overview of how ketamine works in the brain.

Central sensitization. ME/CFS shares clinical and mechanistic overlap with other central sensitization syndromes, including fibromyalgia. Central sensitization describes a heightened sensitivity of the central nervous system to sensory input that amplifies pain, fatigue, and cognitive symptoms. Ketamine's ability to interrupt central sensitization through NMDA receptor blockade is well documented in pain medicine, which is part of the rationale for studying it in ME/CFS.

Neuroplasticity deficits. ME/CFS patients often report memory, attention, and processing difficulties that may reflect impaired neuroplasticity, the brain's capacity to form and reorganize synaptic connections. Ketamine promotes rapid synaptogenesis through brain-derived neurotrophic factor (BDNF) release and activation of the mTOR pathway, which researchers believe could help restore synaptic function in circuits affected by the disease.

As of 2026, evidence for ketamine in ME/CFS is limited to case reports, small open-label observations, and mechanistic research. No large randomized controlled trials have been completed specifically in ME/CFS patients, and ketamine is not an established treatment for the condition.

The most relevant data comes from overlapping conditions. Several controlled trials have found that ketamine infusions reduce pain and improve function in fibromyalgia patients, and some researchers consider fibromyalgia and ME/CFS part of the same clinical spectrum, which makes those findings indirectly relevant. Studies of ketamine for chronic neuropathic pain have occasionally reported improvements in fatigue and cognitive function as secondary outcomes, though these were not the primary focus of the research. Because ME/CFS frequently co-occurs with depression, ketamine's demonstrated efficacy in treatment-resistant depression may also benefit ME/CFS patients who have a comorbid mood disorder.

Published case reports have described individual ME/CFS patients who experienced improvements in fatigue severity, cognitive function, and pain following ketamine infusions, with some effects lasting days to weeks after a single infusion. Case reports cannot establish causation, but they provide a preliminary signal that has helped justify formal research interest. A 2014 PET imaging study published in the Journal of Nuclear Medicine, indexed on PubMed, is among the most cited evidence for widespread neuroinflammation in ME/CFS patients and helped establish the biological rationale researchers now point to when discussing ketamine.

Several research priorities could clarify whether ketamine has a real role in ME/CFS care: randomized controlled trials that enroll ME/CFS patients specifically and track fatigue severity and cognitive function as primary outcomes, biomarker-guided studies that stratify patients by neuroinflammatory markers or glutamate levels to find subgroups most likely to respond, neuroimaging studies examining whether ketamine changes patterns of microglial activation, and long-term safety data specific to this patient population.

Ketamine is not an established treatment for ME/CFS, but its pharmacological profile, including anti-inflammatory effects, NMDA receptor antagonism, neuroplasticity enhancement, and anti-central-sensitization properties, aligns with several proposed disease mechanisms. Current evidence is preliminary and not sufficient to recommend routine use. The mechanistic rationale is strong enough to justify formal clinical investigation, and patients considering this option now should treat it as an experimental, off-label decision made in partnership with an experienced provider. Our guide on what a psychiatrist wants patients to consider before starting ketamine covers questions relevant to any off-label use.